Muscle Tears & Strains
Peptides discussed for pulled muscles and hamstring, calf, and quad strains — BPC-157, TB-500, MGF, PEG-MGF — with the rat muscle-healing evidence, the contested MGF science, why rehab still drives return to play, and the WADA status every tested athlete needs to know.
A muscle strain — a 'pulled' or 'torn' muscle — is damage to muscle fibers, most often where muscle meets tendon (the myotendinous junction), usually while the muscle is contracting as it lengthens: sprinting, kicking, lunging, or decelerating. The hamstrings are the classic site — hamstring injury is the single most common injury in European professional football — followed by the calf (including 'tennis leg' in the inner calf), the front of the thigh, and the groin. Severity runs from a mild strain with a few days of tightness, through partial tears that take weeks, to complete ruptures; injuries that extend into a muscle's internal tendon generally take longer to recover.
The good news is that skeletal muscle regenerates well. Satellite cells — the muscle's resident stem cells — repair focal damage and rebuild fibers that are lost entirely, and most strains heal without surgery. Management has shifted in recent years from rest, immobilization, and protection to early activation and progressive loading. In a randomized trial of Swedish elite footballers, a hamstring rehab protocol built around lengthening exercises returned players to full training in an average of 28 days, versus 51 days with conventional exercises. The real problem is not healing but re-injury: pooled data from hamstring trials put re-injury at around 15%. A few muscle injuries do need surgery and are time-sensitive — a complete tear of the hamstring tendons off the sitting bone is the most common example.
Athletes want a faster return and a lower chance of re-injury, which is why 'best peptide for a torn muscle' is such a common search. BPC-157 has the most muscle-specific animal data, TB-500 is usually stacked with it, and MGF and PEG-MGF are pitched specifically at muscle repair. Most people searching for this are athletes, and all four peptides are banned under the WADA code. This page covers what the evidence shows, where it is contested, and the anti-doping reality. It is informational, not medical advice.
Peptides discussed for Muscle Tears & Strains
BPC-157
Gastric Peptide
A synthetic peptide derived from a protective protein found in gastric juice, widely discussed for tissue repair and recovery.
TB-500
Tissue Repair Peptide
A synthetic version of the active region of thymosin beta-4, widely used for tissue repair, wound healing, and recovery from injuries.
MGF
Growth Factor Splice Variant
A splice variant of IGF-1 produced in response to mechanical stress on muscles, promoting satellite cell activation and muscle repair.
PEG-MGF
PEGylated Growth Factor
A PEGylated version of MGF with extended half-life for systemic muscle growth and recovery effects.
How peptides target muscle tears & strains
BPC-157 has a small cluster of rat muscle studies from the Sikiric group in Zagreb. In a 2006 study it improved healing of a fully cut quadriceps muscle. In a 2008 crush-injury model of the calf muscle group, BPC-157 given by intraperitoneal injection or as a topical cream for 14 days reduced bruising and swelling, prevented contracture of the injured leg, improved muscle enzyme markers, and restored function. A 2010 study found it reversed the healing impairment caused by the corticosteroid methylprednisolone. And a 2021 study detached the quadriceps tendon from its muscle — a myotendinous junction defect that does not heal on its own in rats — and found that injected or oral BPC-157 restored the junction by days 28–42 and counteracted the progressive muscle wasting seen in controls. That last model is the most relevant to human strains, because the myotendinous junction is where most hamstring and calf strains happen.
TB-500 is the synthetic fragment marketed as thymosin beta-4's active region. Its appeal is cell migration, actin remodeling, and new blood vessel formation, and it is usually stacked with BPC-157 for muscle and soft-tissue injuries. Its supporting data come mainly from full-length thymosin beta-4 in wound, eye, heart, and ligament models; we could not find a study of TB-500 in a skeletal muscle strain or tear model.
MGF (mechano growth factor) is a splice variant of IGF-1 that muscle produces after loading or damage. Geoffrey Goldspink's group proposed in the 1990s that its unique tail segment (the E-domain) activates satellite cells and expands the stem-cell pool before repair begins, and synthetic MGF and its longer-lasting PEGylated version, PEG-MGF, are sold on that premise. The premise is contested. In 2014, researchers at two pharmaceutical companies tried to reproduce the claimed effects and found that the MGF peptide did not increase proliferation of mouse or human muscle cells or primary muscle stem cells, while mature IGF-1 did. A 2018 animal study found that boosting MGF in injured muscle delayed the clearance of inflammatory immune cells and did not obviously improve regeneration. Synthetic MGF also degrades within minutes, and adding PEG changes how it behaves in the body.
What the evidence shows
No human trial has tested BPC-157, TB-500, MGF, or PEG-MGF for muscle strains or tears. For BPC-157 the animal results are consistent but come almost entirely from one research group, use injuries — crushes, clean surgical cuts, tendon detachments — that differ from an eccentric strain in a trained athlete, and measure rat function and enzyme levels rather than what matters to people: days to return to play and the risk of re-injury. A 2025 systematic review found that 35 of 36 BPC-157 musculoskeletal studies were preclinical and that no clinical safety data exist. For TB-500, muscle-specific evidence is thinner still. For MGF and PEG-MGF, even the cell-level mechanism has failed an independent replication attempt, and there are no human pharmacokinetic, dosing, or efficacy data.
The conventional evidence is humbling for anyone hoping an injection will speed things up. In the Dutch HIT trial, a double-blind, placebo-controlled study of 80 athletes with acute hamstring injuries, platelet-rich plasma injections did not shorten return to play or change re-injury rates over a year. A 2026 meta-analysis of six randomized trials (277 participants) found platelet-rich plasma shortened return to play by about 8.6 days on average, but with very high variation between trials, low-to-moderate certainty, and no change in re-injury. A 2023 review in Nature Reviews Disease Primers noted that many medications and injections are used to try to accelerate muscle recovery despite very limited evidence that they work.
The intervention with the strongest randomized evidence is the least exotic one: well-designed, progressive loading rehab, especially lengthening-type exercise for the hamstrings. Any peptide would have to add to that foundation, and that has not been shown.
What to expect
Protocols commonly discussed — not prescriptions — include BPC-157 at 200–500 mcg by subcutaneous injection once or twice daily for two to four weeks or longer, often injected near the injured area in community practice (the rat muscle studies used intraperitoneal injection, oral dosing, or topical cream rather than local injection); TB-500 at 2–2.5 mg twice weekly during a four-to-six-week loading phase; MGF at 100–200 mcg injected into the trained muscle after workouts; and PEG-MGF at around 200 mcg two to three times weekly. None of these doses comes from human trials — for MGF and PEG-MGF there are no human dosing data at all — and any use should be supervised by a clinician.
Mild and moderate strains usually heal over days to a few weeks on their own, so a fast recovery on a peptide tells you little about what the peptide did. The bigger risk is the classic re-injury pattern: feeling better before the tissue has regained full strength and length, then returning to sprinting too early. Return-to-play decisions should rest on objective criteria — full strength, pain-free sprinting and lengthening, sport-specific drills — not on how quickly pain faded.
Do not expect any peptide to reattach a tendon pulled off the bone, prevent re-injury, or leave the muscle stronger than before the strain. If a peptide program is being sold as a way to skip or shorten rehab, it is being oversold.
Important caveats
For tested athletes, this is the first thing to know: BPC-157 is named on the 2026 WADA Prohibited List under S0 (non-approved substances), and TB-500 (a thymosin-β4 derivative) and MGF/PEG-MGF (mechano growth factors) are named under S2.3 — all banned at all times, in and out of competition. Anti-doping labs have published detection methods for TB-500 and MGF, and athletes have already been sanctioned for BPC-157 and TB-500. WADA applies strict liability, so 'I only used it to heal an injury' is not a defense, and a therapeutic use exemption is not a realistic route for substances with no regulatory approval anywhere. Research-chemical products can also be mislabeled or contaminated with other prohibited substances. Athletes in the NCAA, professional leagues, or any WADA-code sport should talk to their team physician before considering any of these.
See a clinician promptly rather than self-treating if you feel or see a gap or dent in the muscle; if there was a pop with heavy bruising high in the back of the thigh and pain when sitting (a tendon pulled off the sitting bone needs surgical assessment, and repair generally goes better within weeks); if you cannot bear weight or walk normally; if swelling is severe and tense with pain out of proportion to the injury, numbness, or tingling (compartment syndrome is an emergency); or if you notice dark, cola-colored urine after a crush injury or extreme exertion (possible rhabdomyolysis). Calf pain and swelling without a clear injury, or after immobilization or travel, can be a blood clot. A firm lump that grows or does not settle over several weeks should be imaged.
None of these peptides is FDA-approved for any muscle injury. BPC-157 and TB-500 were removed from the FDA's 503A 'Category 2' list in April 2026, and the Pharmacy Compounding Advisory Committee voted 8–6 in July 2026 to recommend both for the 503A bulks list; that vote is non-binding and the required rulemaking has not happened, so compounding remains unauthorized. MGF and PEG-MGF are available only as research chemicals labeled 'not for human use', with no regulated supply at all. People who are pregnant or breastfeeding, under 18, or who have active or recent cancer should avoid these peptides, given their growth-factor and angiogenic mechanisms.
Frequently asked questions
What is the best peptide for a muscle tear or pulled muscle?
BPC-157 has the most muscle-specific evidence — rat studies of crushed, cut, and tendon-detached muscle all showed faster healing — and TB-500 is usually stacked with it. MGF and PEG-MGF are marketed for muscle repair, but their core mechanism failed an independent replication attempt in 2014. None has been tested in human muscle strains, none is FDA-approved, and all four are banned by WADA. The intervention with the best randomized evidence is progressive loading rehab, and any peptide would only ever be an unproven add-on to it.
Does BPC-157 help a hamstring strain?
It has never been studied in human hamstring injuries. The most relevant animal study (2021) found BPC-157 restored a damaged junction between the quadriceps muscle and tendon in rats — the same muscle-tendon junction where most hamstring strains occur. That makes the idea plausible, not proven. Hamstring recovery is driven mostly by rehab: in one randomized trial, lengthening-focused exercises cut return to training from 51 to 28 days, a bigger effect than any injection has shown. BPC-157 is also prohibited by WADA.
Can athletes use peptides to recover from an injury?
Not if they are subject to drug testing. BPC-157, TB-500, MGF, and PEG-MGF are all prohibited by WADA at all times, including out of competition and during injury rehab. Strict liability means the reason for use does not matter, detection methods exist, and athletes have been sanctioned. A therapeutic use exemption is not a realistic route for unapproved substances. Tested athletes should work with their team physician on evidence-based rehab instead.
Do MGF or PEG-MGF heal torn muscle?
There is no human evidence that they do. The theory comes from Goldspink's work showing muscle makes an IGF-1 variant (MGF) after loading, and a proposal that its tail segment activates muscle stem cells. When researchers at two pharmaceutical companies tried to reproduce that effect in 2014, the MGF peptide did nothing measurable to muscle cells or muscle stem cells, while mature IGF-1 worked. Synthetic MGF also breaks down within minutes. Both forms are WADA-prohibited and sold only as research chemicals.
How long does a pulled hamstring take to heal, and can peptides speed it up?
Mild strains often settle within one to three weeks; more significant tears commonly take four to eight weeks or longer, and injuries involving the internal tendon or a stretching-type mechanism take longer still. No peptide has been shown to shorten that in people. Even platelet-rich plasma, which has been tested in randomized trials, produced at best a modest and inconsistent reduction in return-to-play time with no change in re-injury. The biggest controllable factors are a structured loading program and not returning before strength and sprinting are fully restored.
Which peptides are used for injury recovery in general?
BPC-157 and TB-500 are the most discussed for soft-tissue injuries across the board, and GHK-Cu comes up for skin and collagen. The evidence differs by tissue, so it is worth reading the page for your specific injury: tendonitis and tendon injuries, ACL and ligament injuries, rotator cuff injuries, and back pain each have their own evidence summary. Across all of them the pattern is the same — consistent animal data, essentially no controlled human trials, and a WADA ban for the main candidates.
References
- Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the ratPreclinical
Novinscak and colleagues, Surgery Today 2008. In rats with a crushed gastrocnemius muscle complex, BPC-157 given intraperitoneally or as a topical cream for 14 days reduced hematoma and edema, prevented leg contracture, improved muscle enzyme markers, and restored function. One of the core muscle-injury papers behind BPC-157's recovery reputation — a crush model, not an athletic strain.
- Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in RatsPreclinical
- Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid applicationPreclinical
- Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cellsPreclinical
Fornaro and colleagues, American Journal of Physiology – Endocrinology and Metabolism 2014. Researchers at two pharmaceutical companies could not reproduce MGF's claimed effects: the peptide did not increase proliferation of mouse or human myoblasts or primary muscle stem cells, nor delay their differentiation, whereas mature IGF-1 produced a clear proliferative response. The key independent challenge to the mechanism MGF and PEG-MGF are sold on.
- Acute hamstring injuries in Swedish elite football: a prospective randomised controlled clinical trial comparing two rehabilitation protocolsRandomized Controlled Trial
- Rationale, secondary outcome scores and 1-year follow-up of a randomised trial of platelet-rich plasma injections in acute hamstring muscle injury: the Dutch Hamstring Injection Therapy studyRandomized Controlled Trial
- Effects of percutaneous platelet-rich plasma injection on return-to-play after acute hamstring muscle injury: a systematic review and meta-analysisMeta-Analysis
- Traumatic muscle injuryReview
Part of these goals
Related conditions
Peptide families relevant to Muscle Tears & Strains
Stacks that overlap
- Wolverine Peptide Stack (BPC-157 + TB-500)
The Wolverine Stack is the most popular peptide recovery combination — BPC-157 for localized tissue repair paired with TB-500 for systemic healing, cell migration, and anti-inflammatory support.
- GLOW Peptide Stack (BPC-157 + TB-500 + GHK-Cu)
GLOW is a popular pre-mixed compounded peptide blend combining BPC-157 tissue repair, TB-500 cell migration, and GHK-Cu collagen remodeling in a single 70 mg vial. Also covers the two-peptide BPC-157 + GHK-Cu pairing for practitioners sourcing vials separately.
- KLOW Peptide Stack (BPC-157 + TB-500 + GHK-Cu + KPV)
KLOW is a pre-mixed four-peptide compounded blend combining BPC-157 and TB-500 systemic repair, GHK-Cu collagen remodeling, and KPV anti-inflammatory coverage in a single 80 mg vial. It extends the popular GLOW formulation with an explicit anti-inflammatory layer.
Updated 2026-10-05